Atlas Trials

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Clinical trial NCT04659499 · UNKNOWN

Trial details

NCT number
NCT04659499
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Early Breast Cancer
Start date
2021-01-01
Primary completion
2022-06-01
Enrollment
261

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.